Video Experimental Relacionado
Updated: May 16, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
La orientación selectiva de nucleófilos de sitios activos distintos por inhibidores irreversibles de la kinasa de la
Nathan N Gushwa1, Sumin Kang, Jing Chen
1Howard Hughes Medical Institute, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California 94158, United States.
Journal of the American Chemical Society
|November 30, 2012
Resumen
Nuevas sondas químicas apuntan con precisión a las quinasas de la familia Src en las células vivas. Estas herramientas ayudan a comprender la selectividad de los fármacos e identificar qué quinasas se ven afectadas por tratamientos como el ponatinib.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Biología Química Biología química.
- Farmacología Farmacología.
Sus antecedentes:
- Las quinasas de la familia Src son cruciales para la salud y las enfermedades humanas.
- Los fármacos existentes dirigidos a estas quinasas carecen de selectividad.
- La evaluación de la selectividad de la quinasa en las células vivas es un reto.
Objetivo del estudio:
- Diseñar y validar nuevas sondas químicas para las quinasas de la familia Src.
- Para permitir el etiquetado selectivo y el perfil de las kinasas endógenas en las células.
- Investigar la selectividad del fármaco ponatinib contra las quinasas de la familia Src.
Principales métodos:
- Desarrollo de dos sondas químicas basadas en nucleósidos (1 y 2) con etiquetas de alquino.
- La sonda 1 tiene como objetivo una lisina conservada; la sonda 2 tiene como objetivo una cisteína variable.
- Utilizando sondas para el perfilado competitivo de inhibidores de la kinasa en células intactas.
Principales resultados:
- Ambas sondas etiquetaron eficientemente sus objetivos de quinasa endógena en las células.
- La sonda 1 mostró una amplia reactividad, mientras que la sonda 2 exhibió selectividad para las quinasas específicas.
- Ponatinib inhibió selectivamente la quinasa Lck de las células T, con un impacto mínimo en Fyn o Src.
Conclusiones:
- Las sondas químicas desarrolladas permiten un perfil preciso de las quinasas de la familia Src en los sistemas vivos.
- Estas sondas facilitan la evaluación de la selectividad del fármaco frente a distintos subconjuntos de quinasa.
- Los hallazgos revelan la acción inhibidora específica de ponatinib en Lck dentro de la familia Src.
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
02:34Enzymes
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...